# Olomorasib

Source: https://onco.cc/drugs/olomorasib/  
OnCo record `olomorasib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Olomorasib is Lilly's KRAS G12C pill, designed to combine safely with immunotherapy in first-line lung cancer.

## Summary

Second-generation covalent G12C inhibitor with a cleaner liver profile than sotorasib in combination with pembrolizumab (ORR 74% in first-line PD-L1 ≥50%, JTO 2025). Breakthrough Therapy designation with pembrolizumab in untreated KRAS G12C NSCLC and in KRAS G12C pancreatic cancer. Phase 3 SUNRAY-01 (first line ± chemotherapy) and SUNRAY-02 (early-stage) ongoing.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-06
- Code: LY3537982
- Modality: Small-molecule inhibitor (KRAS G12C)
- Mechanism: Covalent KRAS G12C inhibitor.

## Sources

- OncLive: Breakthrough designation: https://www.onclive.com/view/olomorasib-plus-pembrolizumab-earns-breakthrough-therapy-designation-in-untreated-kras-g12c-mutated-nsclc

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [KRAS G12C-mutant colorectal cancer](https://onco.cc/cancers/kras-g12c-colorectal/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)
- trials: [A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07227025/), [A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer](https://onco.cc/trials/nct06119581/), [A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation](https://onco.cc/trials/nct07814417/), [Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)](https://onco.cc/trials/nct04956640/), [Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06890598/)
- biomarkers: [KRAS G12C](https://onco.cc/biomarkers/kras-g12c/)
- roadmaps: [Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall](https://onco.cc/roadmaps/targeted-therapy-roadmap/)
- pathways: [Non-small cell lung cancer (KEGG map)](https://onco.cc/pathways/nsclc-signalling/)

---
JSON: https://onco.cc/api/v1/entities/olomorasib.json